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Abstract
Background: Although extensive HIV drug resistance information is available for the first 400 amino acids of its reverse
transcriptase, the impact of antiretroviral treatment in C-terminal domains of Pol (thumb, connection and RNase H) is poorly
understood.
Methods and Findings: We wanted to characterize conserved regions in RT C-terminal domains among HIV-1 group M
subtypes and CRF. Additionally, we wished to identify NRTI-related mutations in HIV-1 RT C-terminal domains. We
sequenced 118 RNase H domains from clinical viral isolates in Brazil, and analyzed 510 thumb and connection domain and
450 RNase H domain sequences collected from public HIV sequence databases, together with their treatment status and
histories. Drug-naı ¨ve and NRTI-treated datasets were compared for intra- and inter-group conservation, and differences
were determined using Fisher’s exact tests. One third of RT C-terminal residues were found to be conserved among group M
variants. Three mutations were found exclusively in NRTI-treated isolates. Nine mutations in the connection and 6 mutations
in the RNase H were associated with NRTI treatment in subtype B. Some of them lay in or close to amino acid residues which
contact nucleic acid or near the RNase H active site. Several of the residues pointed out herein have been recently
associated to NRTI exposure or increase drug resistance to NRTI.
Conclusions: This is the first comprehensive genotypic analysis of a large sequence dataset that describes NRTI-related
mutations in HIV-1 RT C-terminal domains in vivo. The findings into the conservation of RT C-terminal domains may pave the
way to more rational drug design initiatives targeting those regions.
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Introduction
The HIV-1 RT is the enzyme responsible for synthesizing a
double-stranded integrative cDNA from the single-stranded viral
genomic RNA early in the virus life cycle. HIV-1 RT is a
heterodimer composed of two subunits, p66 and p51; p51 is
derived from the proteolytic processing and removal of C-terminus
(codons 441 to 560) from p66 [1]. The p66 subunit comprises two
major portions, the polymerase (codons 1 to 440) and the RNase
H domains. The polymerase domain encodes the RT fingers,
palm, thumb and connection motifs [2–4]. The RNase H domain
promotes RNA degradation from the DNA:RNA duplex during
reverse transcription. Other RNase H functions include the
removal of the tRNA3
Lys and the removal of the polypurine tract
(PPT), primers for the DNA minus-strand and DNA plus-strand
synthesis, respectively [5–7].
The polymerase RT portion is currently targeted by two classes
of ARV drugs, the nucleoside reverse transcriptase inhibitors
(NRTI) and the non-nucleoside RTI (NNRTI). HIV drug
resistance mutations in this domain are extensively characterized
for these classes of ARV drugs [8]. To date, however, the influence
of connection and RNase H RT domains in NRTI or NNRTI
resistance is poorly understood. Currently the region of RT
selected for sequencing in resistance studies ranges mostly from
codons 1 to 250 [9,10], and does not include these domains.
Recently, Nikolenko et al. pointed out mutations in the RNase H
domain that reduce its activity and concomitantly increase the
resistance to thymidine analogues in vitro [11]. They have also
proposed a new drug resistance mechanism where the lowered
RNase H activity would allow more time for NRTI excision. This
mechanism is also influenced by the connection domain, as point
mutations in the region that contact template-primer affect RNase
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and RNase H domains from treatment-naı ¨ve and NRTI-
experienced patients infected with different HIV-1 subtypes in
the search for structural conservation patterns and for putative
new NRTI-related mutations. This analysis will also enable the
establishment of conserved regions in the connection and RNase
H RT domains, which could be an essential tool for future rational
drug design initiatives targeting those domains.
Methods
Sample collection
Plasma samples from HIV-positive patients, both treatment-naı ¨ve
and HAART-experienced, were collected from three Brazilian
HIV/AIDS reference centers: two in Rio Grande do Sul (RS) state,
Hospital de Clı ´nicas de Porto Alegre and University Hospital of Rio
Grande, and one located in Rio de Janeiro (RJ), Hospital Gaffre ´e e
Guinle. Patients were recruited from 2002 to 2003 in RS and from
2004 to 2006 in RJ. All patients signed a written consent form for
participating in the study, and the Internal Review Boards from all
three Institutions have approved the study.
RNA isolation, nested PCR and RNase H domain
sequencing
HIV viral RNA was isolated from 50 ml of patient’s plasma using
Trizol, followed by cDNA synthesis with Moloney murine leukemia
virus RT and random primers as previously described [13]. Viral
RNase H domain was amplified by nested PCR using Platinum Taq
polymerase (Invitrogen, CA, EUA). The first round was conducted
using primers 59tatacgtaagccacctggattc39 (3762-3783 nucleotide
positions relative to HXB2) and 59cagtctacttgtccatgcatggcttc39 (nt
relative positions 4371-4396) with an annealing temperature of
55uC. The second round was done using primers 59ggtaccagttaga-
gaaagaaccca39 (nucleotide positions 3826-3849) and 59cattgcctctc-
caattactgtgatatttctcatg39 (nt positions 4263-4295) with an annealing
temperature of56uC.A 469-bpfragmentcorresponding to RNase H
codons was amplified, purified and sequenced in an automated ABI
Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA,
USA). Sequences obtained were assembled and manually edited
using SeqMan (DNAStar, Madison, WI, USA).
HIV-1 subtype characterization
To eliminate sample contaminations or mix-ups and to
determine the isolates’ subtype, a FASTA file with all edited
sequences and representative sequences of all HIV-1 subtypes
obtained from Los Alamos HIV database (http://hiv-web.lanl.
gov) [14] was constructed. The HIV-1 subtype of each sample was
determined through phylogenetic inference using the neighbor-
joining method and Kimura 2-parameter model of nucleotide
substitution in the MEGA 2.1 package [15]. One thousand
replicates of bootstrap were performed to infer cluster robustness
and the sequence of HIV-1 group O 99SE-MP1299 (GenBank
acc. no. AJ302646) was used to outgroup the trees [16].
Global thumb, connection, and RNase H domain
sequences
For the conservation analysis of thumb, connection and RNase
H domains and potential drug resistance mutations, we searched
all available HIV-1 group M sequences spanning all subtypes (A–
D, F–H, J and K) and CRF01_AE and CRF02_AG from the Los
Alamos HIV database (http://hiv-web.lanl.gov) [14] and the
Stanford HIV Drug Resistance Database (http://hivdb.stanford.
edu/) [17]. Only isolates from patients for which treatment
information was available, and which included the use of NRTI,
were included in the analysis. The Stanford database already
includes full treatment history for all sequences. For the Los
Alamos database, ARV-experienced sequences had their GenBank
accession number retrieved, which was used to track treatment
history in the Stanford database. To prevent the use of more than
one sample from the same patient, all sequences obtained were
subjected to phylogenetic inference using the methodology
described above, and for sequences shown to be phylogenetically
close-related only one of them was kept.
Determination of drug-related mutations
In view of potential sequence biases created from comparing
different HIV-1 polymorphisms present in different subtypes, only
subtype B sequences were used for drug-related mutation
comparisons. Sequences belonging to subtype B from treatment-
naı ¨ve and experienced groups were separately aligned using
ClustalX [18] in the freely available program BioEdit v. 7.0.5.3
[19]. A subtype B consensus sequence from treatment-naive
subjects was used as reference in the analysis. Nucleotide
sequences were translated into amino acids and residue differences
were compiled between treatment-naı ¨ve and NRTI-treated
patients. All amino acid differences between both treatment
groups were evaluated by statistical inference using two-tailed
Fisher’s exact test, and a p-value,0.05 was considered significant.
In an attempt to investigate the potential role of specific ARV
drugs in selecting resistance mutations, we have analyzed 28
subtype B sequences from subjects that underwent monotherapy
with AZT (the only drug for which there were cases of single drug
exposure prior to sample collection). Those sequences were
compared to the subtype B drug-naı ¨ve isolates described above
for significance of amino acid residue frequencies.
Structural visualization of HIV-1 RT domains
To facilitate the visualization of conserved positions and the
inferred drug-related mutations, the atomic coordinates of the
crystal structure of HIV-1 BH10 (subtype B) RT in contact with
the DNA:RNA hybrid (PDB entry 1HYS) were used [20]. The
software ViewerLite 5.0 was used to visualize the file and to color
the conservation patterns and mutations which differ significantly
between treatment-naı ¨ve and NRTI-treated groups.
Results
Conservation of RT C-terminal domains
Five hundred and ten sequences of thumb and connection
domains (RT codons 298-440) were retrieved from the databases,
of which 280 were treatment-naı ¨ve (HIV-1 subtype composition:
38 A, 72 B, 73 C, 34 D, 6 F, 4 G, 1 H, 1 K, 44 CRF01_AE and 7
CRF02_AG) and 230 were NRTI-treated (10 A, 188 B, 4 C, 4 D,
20 CRF01_AE and 4 CRF02_AG). For the RNase H domain (RT
codons 441-560), we obtained 450 sequences, of which 276 were
treatment-naı ¨ve (39 A, 66 B, 69 C, 35 D, 7 F, 5 G, 1 H, 1 J, 44
CRF01_AE and 9 CRF02_AG) and 174 were NRTI-treated (1 A,
153 B, 2 F and 18 CRF01_AE).
We successfully amplified and sequenced the RNase H domain
(codons 441-560) of 118 isolates from Brazilian HIV-positive
patients. The phylogenetic inference showed that half of them
belonged to subtype C (n=59) and the other half was assigned to
subtype B (n=59) (data not shown). Regarding ARV treatment
status, 58 patients were naive (B=27 and C=31) and 60 were on
treatment (B=32 and C=28). Together with the sequences from
public databases, we gathered 334 RNase H sequences of drug-
naı ¨ve and 234 RNase H sequences of NRTI-treated patients. For
HIV-1 C-Terminal RT Mutations
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the public databases for further analysis.
Sequences of RT C-terminal domains were aligned, subtyped
by phylogenetic analysis (data not shown), and evaluated by their
extent of codon polymorphisms (Figure 1). In drug-naive isolates,
the number of non-variable sites (defined as sites exhibiting
variation #1%) was 165 (63%), a similar number found among
NRTI-treated isolates (163; 62%). In some cases, sites seemed
more variable in the naı ¨ve isolates than in the NRTI-treated
isolates. This is explained by the different subtype proportions
among those two groups. While 26% of thumb and connection
domain sequences from drug-naı ¨ve subjects were represented by
subtype B, this proportion among treated subjects was of 82%.
Similarly, subtype B accounted for only 28% of RNase H domain
sequences from naı ¨ve subjects, while it accounted for 80% among
treated subjects.
NRTI-selected amino acid variations
We analyzed amino acid variations found in vivo when comparing
NRTI-naı ¨veand treated subjects ateach one of 263codons included
inthe study. Sincea number of amino acid residues are polymorphic
across all HIV-1 group M subtypes, we decided to search for NRTI-
related mutations only among subtype B sequences available.
Subtype B represented alone 51% (260/510) of thumb and
connection domain strains and 51% (288/568) of RNase H domain
strains in our analysis. The results can be seen in Figures 2 and 3.
Fifteen amino acid substitutions had significantly different frequen-
cieswhencomparing drug-naı ¨veand treatment-experienced subtype
B isolates. Of those, 12 had increased prevalence in treated
sequences (R358K, G359S, A360T, A360V, K366R, A371V,
K390R, A400T, I506L, K527N, K530R and Q547K). The
mutations A360V, I506L and Q547K were only seen in subtype B
patients under treatment. The largest difference found was for
mutation K527N, with a frequency 16 times higher in treated
patients (Figure 3). Mutation A371V was seen in 22.6% of treated
versus only 2.3% of naı ¨ve subtype B isolates (10 times lower).
Similarly, mutation K530R was found in 12.1% of treated isolates
versus 1.1% of naı ¨ve isolates. Another mutation, G359S, was found
in 15% of treated isolates, while it was seen only in 3.4% of the drug-
naı ¨ve isolates (Figure 2). Three amino acid substitutions showed
decreased proportions in treatment-experienced subtype B isolates
whencompared to drug-naı ¨ve isolates(I326V,T470N, and K512R).
All 15 statistically-significant amino acid differences between drug-
naı ¨ve and experienced sequences, together with their respective p-
values, can also be seen in Table 1.
The role of specific ARV drugs in selecting the mutations
depicted here is not easily determined, since the vast majority of
treated patients whose viral samples were analyzed have been
subjected to multiple, complex drug combinations prior to sample
collection. In our dataset, none of the connection domain
sequences analyzed was from patients in use of NNRTI, but a
small fraction of the RNase H viral sequence (8.6%; 16/185) had
previous exposure to that drug class. Therefore, we cannot
completely rule out the possibility of a potential influence of
NNRTI in the selection of mutations characterized here. However,
a limited number of those samples (n=28) are from patients older
in the epidemic and exclusively subjected to AZT monotherapy.
We have compared these sequences with those from the drug-naı ¨ve
dataset in the positions pointed out above. It noteworthy that
comparisons were possible only up to RT codon 500, as scarce
sequence information is available after that codon for those viral
sequences. The comparison can be seen in Table 1. Among the 10
mutations analyzed, 4 were significantly found more frequently in
AZT-exposed subjects (A360V, A371V, K390R and A400T).
These mutations are expected to be selected by AZT, and perhaps
by other NRTI, particularly thymidine analogues.
Mutations subjected to selective pressure were highlighted onto
the structural C-terminal domains of HIV-1 RT (Figure 4). In the
connection domain, nine mutations were selected by treatment in
subtype B. The RNase H domain harbored 6 mutations selected
by treatment in this subtype. Interestingly, some of these residues
lie in motifs known to contact the nucleic acid (G359S, A360T/V
and K390R). As expected, the seven amino acid residues that
comprise the RNase H catalytic site (D443, E478, D498, S499,
H539, N545 and D549) were highly conserved and remained
unchanged under NRTI treatment.
Discussion
The present study determined the conserved amino acid
positions of thumb, connection and RNase H domains of HIV-1
Figure 1. Analysis of conservation of HIV-1 RT connection and
RNase H domains from HIV-1-infected drug-naı ¨ve and NRTI-
treated subjects. Amino acid residues are represented as the group M
consensus. Degrees of conservation are color-coded as shown at the
bottom. Conserved motifs (variability below 1%) are boxed.
doi:10.1371/journal.pone.0001781.g001
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naı ¨ve and NRTI-experienced patients has evidenced a total of 86
(33%) invariable sites common to both groups. Other studies
recently published on the polymorphism of PR (codons 1-99) and
RT N-terminal domains (1-320) observed highly conserved sites in
approximately half of PR [21] and in over half of RT N-terminal
domain [22], independent of treatment. In both studies, the
inclusion of non-B subtypes was negligible, with contributions of
only 3.9% in the former study and 4.8% in the latter. The use of
few non-B subtypes in those analyses may explain the high
Figure 2. Comprehensive analysis of amino acid sequence variation in HIV-1 RT thumb and connection C-terminal domains
showing polymorphic variations between subtype B viruses from drug-naı ¨ve and NRTI-treated subjects. Residues are displayed as the
subtype B consensus; other residues found among sequences analyzed are shown below each consensus residue. Numbers shown in subscript for
each residue represent total number of sequences analyzed (in the consensus sequence) and frequencies in viruses (other residues) from drug-naı ¨ve
(left) and NRTI-treated (right) subjects. Residues which differed significantly (p,0.05) in frequency between naı ¨ve and treated patients, as well as the
corresponding changed residues, are boxed in gray.
doi:10.1371/journal.pone.0001781.g002
Figure 3. Comprehensive analysis of amino acid sequence variation in HIV-1 RT RNase H C-terminal domains showing polymorphic
variations between subtype B viruses from drug-naı ¨ve and NRTI-treated subjects. Residues are displayed as the subtype B consensus;
other residues found among sequences analyzed are shown below each consensus residue. Numbers shown in subscript for each residue represent
total number of sequences analyzed (in the consensus sequence) and frequencies in viruses (other residues) from drug-naı ¨ve (left) and NRTI-treated
(right) subjects. Residues which differed significantly (p,0.05) in frequency between naı ¨ve and treated patients, as well as the corresponding
changed residues, are boxed in gray.
doi:10.1371/journal.pone.0001781.g003
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resistance studies is the subtype B. In our study, we found that one
third of RT C-terminal sites are highly conserved, independent of
HIV-1 group M subtypes or treatment status.
Regions of C-terminal RT domains lying closer to the
DNA:RNA hybrid were found conserved, including amino acid
residues that interact with the primer DNA (G359, A360, H361,
K395, E396, T473, N474, Q475, K476, Y501 and I505) and the
template RNA strand (K390, R448, N474, Q475, Q500 and
H539) [20]. Site-directed mutagenesis of RNase H positions N474,
Q475 and Y501 rendered the mutant enzymes inefficient in the
removal of the PPT primer and modified the RNase H cleavage
specificity [23]. In addition, changes at RNase H positions Q475
and Y501 produced defective viruses [24,25]. The essential role of
those positions for RNase H is also reflected in our study, where
they were found highly conserved. Positions T473, Q500 and I505
also had a high degree of conservation. Other two positions (R448
and K476) showed a low variability (2–5% variation).
The motif ETFYVDGA spanning RT codons 438-445 was
highly conserved (0–5% variation), which is consistent with the
fact that it overlaps the protease cleavage site AETFYVD (codons
437-443) located between the connection and the RNase H
domains. Mutagenesis experiments in this motif caused defects in
virion RT and integrase processing [26]. Positions E438, T439,
Y441 and V442 were highly invariable (variation #1%) (Figure 1).
Positions F440 and D443 presented a low degree of variability
(variation 2–5%). Position A437 was the most variable (14%). The
impact of this polymorphism on the efficiency of cleavage remains
to be experimentally determined.
Another conserved region comprises codons 492-511 and
represents the RNase H b4 and aB secondary structures [27].
Amino acids D498, which interacts with divalent cations, and
S499, which is also part of the RNase H catalytic site, lie in this
motif. The motif 535-553 is also conserved, which harbors the
invariable amino acids N545, H539 and D549, this last aspartic
acid also interacting with divalent cations. The five residues D498,
S499, H539, N545 and D549 comprise the RNase H catalytic site
together with two other residues, D443 and E478 [27]. All
positions were highly conserved with the exception of position
D443, with 2% variation found naturally in drug-naı ¨ve patients,
but highly conserved in treated isolates.
The function of the connection domain has not been fully
characterized. The crystal structure of HIV-1 RT has shown five
positions of the connection domain that interact with DNA (G359,
A360, H361, K395 and E396) and a unique position (K390) that
interacts with RNA [20]. These positions are part of the RNase H
primer grip motif, which helps positioning the template:primer at
the RNase H active site. More recently, site-directed mutagenesis
experiments in all those codons showed individual effects on
reducing the RNase H activity either by altering the consensus 2-
LTR circle junctions (H361 and E396) or by inserting tRNA
primers at those junctions during reverse transcription (A360,
H361, T362, K395 and E396) [12]. All mutations decreased the
viral replicative capacity including mutations in residues G359 and
K390. The authors suggested that these mutations weaken the
binding of RT to nucleic acid, therefore affecting RNase H
activity. In contrast to the high conservation seen in residues that
contact nucleic acids in the RNase H domain, only two residues
were highly conserved in the connection domain (H361 and T362;
Figure 1). This can be explained by the proximity of these residues
to the RNase H catalytic site [12]. The remaining residues
presented natural variations within HIV-1 group M (10–70%
variation). It is interesting to note that position 390 in the group M
consensus is an arginine, where in subtype B it is a lysine.
Moreover, the mutation K390R appears to be selected by NRTI
usage in subtype B (Figure 4). The role of specific amino acid
residues at this position and their impact on the primer grip
function deserves further investigation.
The most conserved region of the connection domain encodes
amino acids 387-430, where 38 codons (86%) presented high
conservation (0–4% variation). This is an interesting finding because
this region contains one of two RT sites which interact with the viral
Table 1. Frequency of putative NRTI- and AZT-related mutations found among viruses from patients with NRTI or with AZT
monotherapy exposure
Mutation Frequency Naı ¨ve Frequency NRTI-treated p-value Frequency AZT-treated p-value
I326V 17.2% (15/87) 6.4% (12/188) 0.008 7.1% (02/28) 0.157
R358K 9.2% (08/87) 18.7% (35/187) 0.049 14.3% (04/28) 0.326
G359S 3.4% (03/87) 15% (28/187) 0.004 10.7% (03/28) 0.154
A360T 9.2% (08/87) 17.6% (33/187) 0.028 14.3% (04/28) 0.326
A360V 0% (00/87) 9.1% (17/187) 0.002 14.3% (04/28) 0.003
K366R 4.6% (04/87) 16.7% (31/186) 0.006 10.7% (03/28) 0.225
A371V 2.3% (02/87) 22.6% (42/186) ,0.001 17.9% (05/28) 0.009
K390R 27.6% (24/87) 40.9% (76/186) 0.043 60.7% (17/28) 0.002
A400T 43.2% (32/74) 69% (119/172) ,0.001 71.4% (20/28) 0.001
T470N 6.5% (06/93) 0.6% (01/177) 0.007 3.7% (01/27) 0.841
I506L 0% (00/93) 6.9% (04/58) 0.020 NA** NA
K512R 8.6% (08/93) 0% (00/58) 0.024 NA NA
K527N 1.1% (01/93) 17.2% (10/58) ,0.001 NA NA
K530R 1.1% (01/93) 12.1% (07/58) 0.010 NA NA
Q547K 0% (00/93) 6.9% (04/58) 0.020 NA NA
*Significant p-values at the 0.05 level are boldfaced
**NA, data not available
doi:10.1371/journal.pone.0001781.t001
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the codons had a high degree of conservation among HIV-1 group
M strains. All conserved regions presented here are potential targets
for new drugs aiming to inhibit HIV-1 group M replication.
When we compared subtype B naı ¨ve and treatment-experi-
enced sequence groups, differences between them were found. We
discovered 15 mutations related to NRTI treatment. Until now, all
studies published on HIV RTI drug resistance relied on the N-
terminal half of RT, the target of both RTI drug classes. Such
studies neglected the role of C-terminal RT domains in drug
resistance. In 2005, Nikolenko et al. evidenced the importance of
the RNase H domain to drug resistance. They showed that
mutations which decreased in vitro RNase H activity greatly
increased resistance to AZT and d4T [11]. In the present study,
we did not find any of the RNase H mutations pointed out in the
literature that decreased RNase H activity in vivo. However, three
of the mutations described here (A360V, I506L and Q547K) were
present only in NRTI-experienced isolates. Mutation A360V lies
in a residue that contacts nucleic acid, while mutation I506L is
close to two residues of the RNase H primer grip [20]. We think
that these changes may weaken the RT-DNA:RNA contact,
therefore decreasing RNase H activity, while still maintaining virus
viability in vivo. Such hypothesis was corroborated by recent work
of Delviks-Frankenberry and colleagues [29], through alanine-
scanning mutagenesis in RNase H primer grip residues. The
authors showed concomitant decrease of RNase H activity and
increase of AZT resistance by knocking out residues G359, A360,
and K390. Each of these mutations did not confer resistance by
itself, but in combination with thimydine analog mutations the fold
change in resistance to AZT was from 2.5 to 6.5 times higher
when compared to viruses carrying only TAMs [29]. All these
residues are described herein as related to NRTI treatment.
In view of potential biases created by differences in subtype
distribution in drug-naı ¨ve and NRTI-experienced sequence
groups, we conducted an exclusive analysis of subtype B, the
one with the largest number of isolates sequenced, particularly
those on NRTI treatment. A small number of NNRTI-
experienced patients was present in the dataset, and as possible
interactions between NRTI- and NNRTI-selected mutations is
known to occur, we cannot completely discard a putative effect of
NNRTI in the selection of mutations described here. Nine changes
in the connection domain and 6 in the RNase H domain were
found related to treatment (Figures 2 and 3). Some changes are
within (G359S, A360V/T and K390R) or close (R358K and
A400T) to the primer grip, while another is close to the RNase H
catalytic site (Q547K; Figure 4). Experimental evidence for the
role of those residues in drug resistance is just starting to emerge,
but is rapidly accumulation. Nikolenko and colleagues have
recently identified eight mutations in the connection domain
(E312Q, G335C/D, N348I, A360I/V, V365I, A376S) that
increase the resistance to AZT in phenotyping assay [30]. In our
analysis, mutation A360V was found significantly associated with
NRTI treatment. Interestingly, the study by Nikolenko et al. also
reported that the reversion of mutation I326V increased AZT
resistance [30]. Here, the decrease in frequency of this mutation
was associated with treatment (Figures 2 and 3). Additionally,
Cane et al. correlated some mutations in the RT connection
domain with TAMs, G359S, A360V/T and A371V [31]. Once
more, all those changes were evidenced in our analyses.
Among the NRTI-related mutations characterized herein, four
of them have been associated with AZT in patients with exclusive
exposure to that drug. Those included mutations A360V and
A371T, found in patients with TAMs [32]. We may speculate that,
in addition to AZT, other thymidine analogues (such as d4T) may
also select for those mutations, but additional experimental and
analytical data is necessary to confirm this hypothesis.
This work was the first to comprehensively evaluate genotypic
variation in the C-terminal domains of RT in the context of drug
resistance in vivo and in most HIV-1 subtypes. The findings
corroborate data by other studies [11,29–30] and expand our
knowledge about the influence of C-terminal RT domains in
antiretroviral drug resistance. We also elaborated a panel of
conserved residues for HIV-1 group M independent of treatment
which we believe is useful for the design of new drugs that target
those domains. The role of RT mutations characterized herein is
still undetermined, but they may become pivotal in developing
optimized genotyping HIV drug resistance algorithms.
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Figure 4. Three-dimensional structure of HIV-1 RT connection
(A) and RNase H (B) domains in contact with template viral DNA
showing codons significantly associated with NRTI treatment.
The atomic coordinates of HIV-1 RT isolate BH10 (entry 1HYS of the
Brookhanven Protein Data Bank) was downloaded into the visualization
software ViewerLite v. 5.0 and then manually colored. Subtype B-related
substitutions with statistical significance are shown in red. Amino acid
residues with asterisks denote those which interact with nucleic acid.
Additional residues which interact with nucleic acid, but not found to
be selected by treatment in our analysis, are shown in green. Amino
acid residues depicted in orange in panel (B) represent the RNase H
catalytic site.
doi:10.1371/journal.pone.0001781.g004
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